rss
Br J Ophthalmol 2008;92:689-693 doi:10.1136/bjo.2007.128371
  • Laboratory science
    • Original Article

VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity

  1. C Pieh1,
  2. H Agostini1,
  3. C Buschbeck1,
  4. M Krüger2,
  5. J Schulte-Mönting3,
  6. U Zirrgiebel4,
  7. J Drevs5,
  8. W A Lagrèze1
  1. 1
    Department of Ophthalmology, University Hospital Freiburg, Freiburg, Germany
  2. 2
    Department of Pediatrics, University Hospital Freiburg, Freiburg, Germany
  3. 3
    Department of Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany
  4. 4
    ProQinase GmbH, Clinical Biomarker Analysis, Freiburg, Germany
  5. 5
    Department of Cancer Biology, University of Freiburg, Freiburg, Germany
  1. Dr C Pieh, Universitäts-Augenklinik, Freiburg, Killianstrasse 5, 79106 Freiburg, Germany; christina.pieh{at}uniklinik-freiburg.de
  • Accepted 2 February 2008
  • Published Online First 11 April 2008

Abstract

Aim: To study prospectively the plasma levels of vascular endothelial growth factor (VEGF-A), its soluble receptors sVEGFR-1, sVEGFR-2 and soluble Tie2 in premature infants. To identify their changes related to the onset of retinopathy of prematurity (ROP).

Methods: Blood samples of 63 preterm infants born at a postmenstrual age (PMA) of 23–32 weeks were obtained between 5 days and 15 weeks after birth. 42 infants had no ROP, two had stage 1, nine stage 2 and 10 stage 3. Of these, four infants were treated with retinal photocoagulation. VEGF-A, sVEGFR-1, sVEGFR-2, and sTie2 were measured in the plasma with a sandwich enzyme immunoassay using factor-specific monoclonal mouse antibodies. The time course of concentrations plotted by kernel smoothing in infants with and without ROP were compared and a paired subgroup with analysis of variance was analysed.

Results: ROP patients had raised plasma levels of sVEGFR-2 and sTie2 compared with premature infants without ROP. VEGF-A and sVEGFR-1 levels were similar in both groups. Analysis of a subgroup with pairs of measurements, one before 32 weeks and one after 36 weeks, showed a significant increase in sTie2 after 36 weeks of PMA independent of ROP (p = 0.03).

Conclusion: This is the first study to measure plasma levels of angiogenic factors in ROP. Similar VEGF-A plasma levels in infants with and without ROP suggest that pathogenic retinal angiogenesis in ROP is mainly driven by local VEGF-A synthesis. Elevated plasma levels in active ROP were observed for sVEGFR-2 and sTie2. These increases have yet to be confirmed as predictive values for ROP.

Footnotes

  • Competing interests: None declared.

  • Ethics approval: This study adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the Albert-Ludwigs-University Freiburg, Germany.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2007.128371v1
    2. 92/5/689 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.